Given that quite a few shareholders have been in touch with the company and told an update is coming, i would be hugely surprised if we dont get this update next week.At the very least it will reconfirm the guidance which in itself will be helpful to confidence. Hopefully it will also give news on deals. If the latter then i also think we will see a significant move in the share price taking us into the 400s and setting us up nicely for the 500s when the interims are out in 7 weeks. Happy weekend to all |
#8422 Seriously, yes. Agreed. |
They say every day is a school day Jasie and today for me was the Walkie Talkie Sky Garden. Hope it's a good trip. |
We nearly always drop all the gains we have made in the week on a Friday Dom. We do seem undervalued but there is nothing that we can do about that. Never mind, the sun's up and I'm off for a few drinks in the Walkie Talkie Sky Garden! Have a pleasant weekend all! |
US tech selloff today might be a more accurate reason? |
Friday always used to be good in the old - pre-Covid - days, but with noone at work these days....... |
 I'm sure we both have some owner's bias too Dom, but when you consider that a significantly bigger company is worth less after the pandemic than before it, well it shows just how far OXB has slipped away from fair value.
I totally agree with this notion that at some point there is an event which sends everything charging back the other way, but as we are currently 370p from a low of about 170p, I think maybe a better description is that the pendulum is already swinging back and that any good news from now on is just going to keep that pendulum going.
I'm sure that there will have been some profit taking already - particularly for those simply studying the trend rather than studying the company, but for me fair value is back in the FTSE250 and I still expect that this year.
A lot of the possibilities I type about are just that (e.g. the Serum agreement might be malaria and so on) but remember the big new CAR-T deal announced in March isn't a possibility, it's a signed contract.
(quote)
Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based manufacturing facility.
(unquote)
At some point, maybe the interims / maybe before, they have to tell us what that is worth and who it is for. It's potentially worth more than our supply contract for Novartis and of course is ongoing.
As you know, not covering costs (in OXB's case due to loss of AZ vaccine work, Homology leaving this business sector and general post-pandemic economic conditions) is not a good place and we have been punished.
Covering costs (there or there about this year) is a much better place and should have us back in the FTSE250.
Cumulatively adding big contracts after covering costs, especially multi-year commercial supply contracts, is happy days.
Seems a lower volume day so far today though. |
It is well known that I share Mr President's belief that impressive growth will be revealed whenever the company do share their status with us. Personal opinion - when we hear news it will kick off a quick 25% rise. Bring it on! |
Maybe a clue as we approach today's close. If news next week we could expect a lot of late buys. |
I suspect that noone works in the City on a Friday.... |
In my book of sweeping statements based upon the first hour of trading, I'm going to say this is looking a lot more like a one step back day than the two steps forward variety at present.
I have other news about bears and popes on request. |
As I have said before no update because there is little to add to previous However the fact that they say they will update up to Sept , so close to the interims means it will be no ordinary update more a significant RNS |
Pretty big volume again today. |
I think a good clue here would be how much they are paying Frank (which we of course don't know). If it's some token amount (or less) then I would be certain he is there to keep an eye on things for OXB's benefit relating to something we don't know about yet.
As we all know, OXB have spent a fortune in both continually developing their own tech (current LentiVector being 4th generation) and buying in latest generation AAV and such. If some kind of tie-up with ArcticZymes is a shortcut to the next level and keeps OXB at the front, then it needs to be done before someone else does it.
Whatever that possible deal might be, and obviously this is speculation, is a pretty limitless list from simply an exclusive / non-exclusive rights deal (with or without royalties), through swapping tech, to swapping shares - and that goes without mentioning our very recently enlarged cash pile.
A point to bear in mind here might be the way ArcticZymes look at OXB's customer base - where a deal with OXB could be viewed as 30 to 50 little (and not so little) deals in one sweep.
If there is something coming then OXB would have known about this long before ArcticZymes announced at the end of June, which would fit quite nicely in explaining some other mysteries.
As always, the real story (if there is anything in it) will become clear in time. |
We clearly have some world leading technology particularly in lentiviral vectors but it is just possible that Arcticzymes have something which will improve our lead even further? Hopefully anyway! |
I've commented previously that the role of the CEO is to drive the company forward and all their energy and time should be in doing that.
It would be interesting if a welder in an engineering works making railings told management he had taken the position of a welder at an engineering works down the road two days a month fabricating pressure vessels. In doing so he would gain greater exposure to modern welding and fabricating techniques, he would be more marketable in the future with his gained skills and the company would benefit because he could weld the railings they manufactured even better. Obviously his salary would increase due to income from both revenue streams.
Only wondering, don't shoot me down! |
No. It’s not normal.
In my view it’s also not very acceptable.
All effort should be directed to his ceo role.
I’m surprised that some of the institutions haven’t kicked off |
1996 they floated on AIM and very quickly went main market. I've owned OXB shares for well over 20 years and the AIM part is long before me. All the time I've owned though, people have regularly incorrectly labelled OXB as AIM. I don't know why that is.
But today I'm more perplexed by this idea that it would be normal for the CEO of Boeing to sit on the non-exec advisory board of Airbus, that the Barratt CEO would do that for Wimpey, the boss of Tesco advising ASDA, and so on.
Appreciate that there is often Eurovision style voting here, but even so - do we really think that's normal? I don't. |
All of them :¬) Thanks for the pointer - I've only just realised that oxb is main market listed - so even less to worry about :¬)) |
Which AIM company would that be? |
I'd have thought a CEO would be unlikely even to be offered a NED post that wasn't in some way related to his existing job - that's what the second company is looking for after all (except perhaps in services such as law and finance, where skills are presumed to be transferable).
Lucky that AIM CEOs are people of such high integrity! |
What about the seeming conflict of interest though red?
OXB have a lot of purification IP for viral vector applications. Half ArcticZyme's business seems to be viral vector purification.
Surely Frank can't be CEO of one company doing that and Chairman of another with a competing technology?
Unless of course there is some relationship coming which might finally explain the mystery of why none of the senior staff bought in the last open period? |
I'm my UK plc experience (now ancient!) the CEO would always take a non-exec role at another company, never more then one, but not necessarily smaller Non exec chairman is a bit more work, but with a very small company it would be ok. The reasoning was that they needed exposure to other board dynamics, better to understand the governance scrutiny they came under as CEO. It was also to help them prepare for the raft of NED roles they would inevitably pick up on retirement! |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
